JP2020191868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020191868A5 JP2020191868A5 JP2020102992A JP2020102992A JP2020191868A5 JP 2020191868 A5 JP2020191868 A5 JP 2020191868A5 JP 2020102992 A JP2020102992 A JP 2020102992A JP 2020102992 A JP2020102992 A JP 2020102992A JP 2020191868 A5 JP2020191868 A5 JP 2020191868A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cells
- antigen
- expression vector
- host cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 108091008874 T cell receptors Proteins 0.000 claims 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 102100035683 Axin-2 Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 101000874569 Homo sapiens Axin-2 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096165P | 2014-12-23 | 2014-12-23 | |
| GB201423016 | 2014-12-23 | ||
| US62/096,165 | 2014-12-23 | ||
| GB1423016.3 | 2014-12-23 | ||
| GBGB1501017.6A GB201501017D0 (en) | 2014-12-23 | 2015-01-21 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB1501017.6 | 2015-01-21 | ||
| JP2017518096A JP6906156B2 (ja) | 2014-12-23 | 2015-12-16 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518096A Division JP6906156B2 (ja) | 2014-12-23 | 2015-12-16 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020191868A JP2020191868A (ja) | 2020-12-03 |
| JP2020191868A5 true JP2020191868A5 (enExample) | 2021-07-26 |
| JP7346361B2 JP7346361B2 (ja) | 2023-09-19 |
Family
ID=66846825
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020102004A Active JP7109801B2 (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102005A Active JP7358299B2 (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102006A Pending JP2020191866A (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102993A Active JP7448423B2 (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102991A Ceased JP2020191867A (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102992A Active JP7346361B2 (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020106475A Expired - Fee Related JP7026411B2 (ja) | 2014-12-23 | 2020-06-19 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2023078113A Pending JP2023100927A (ja) | 2014-12-23 | 2023-05-10 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2025098413A Pending JP2025134788A (ja) | 2014-12-23 | 2025-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020102004A Active JP7109801B2 (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102005A Active JP7358299B2 (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102006A Pending JP2020191866A (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102993A Active JP7448423B2 (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102991A Ceased JP2020191867A (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106475A Expired - Fee Related JP7026411B2 (ja) | 2014-12-23 | 2020-06-19 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2023078113A Pending JP2023100927A (ja) | 2014-12-23 | 2023-05-10 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2025098413A Pending JP2025134788A (ja) | 2014-12-23 | 2025-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Country Status (29)
| Country | Link |
|---|---|
| US (11) | US12076380B2 (enExample) |
| EP (1) | EP4461371A3 (enExample) |
| JP (9) | JP7109801B2 (enExample) |
| KR (4) | KR102435015B1 (enExample) |
| AU (1) | AU2022268329A1 (enExample) |
| CL (1) | CL2021001479A1 (enExample) |
| CO (1) | CO2017003772A2 (enExample) |
| CR (1) | CR20210289A (enExample) |
| CY (5) | CY1122491T1 (enExample) |
| DK (1) | DK3236985T4 (enExample) |
| ES (5) | ES2896919T3 (enExample) |
| FI (1) | FI3236985T4 (enExample) |
| HR (5) | HRP20211754T1 (enExample) |
| HU (5) | HUE055489T2 (enExample) |
| IL (1) | IL281752A (enExample) |
| LT (5) | LT3626731T (enExample) |
| MA (6) | MA49155B1 (enExample) |
| MD (5) | MD3545965T2 (enExample) |
| MX (6) | MX2020011794A (enExample) |
| MY (2) | MY199068A (enExample) |
| PE (1) | PE20211740A1 (enExample) |
| PL (4) | PL3626731T3 (enExample) |
| PT (5) | PT3236985T (enExample) |
| RS (1) | RS62575B1 (enExample) |
| SG (2) | SG10202102698VA (enExample) |
| SI (2) | SI3616706T1 (enExample) |
| TW (3) | TWI794679B (enExample) |
| UA (1) | UA124331C2 (enExample) |
| ZA (1) | ZA201701762B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202102698VA (en) * | 2014-12-23 | 2021-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
| CN114720691B (zh) * | 2022-05-10 | 2022-12-09 | 深圳粒影生物科技有限公司 | 一种检测生物标志物的试剂盒及其制备方法和应用 |
| CN119391711A (zh) * | 2024-10-17 | 2025-02-07 | 合肥综合性国家科学中心大健康研究院 | 小蛋白UFD1s及其在预防、治疗和诊断非酒精性脂肪性肝炎中的应用 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IE53176B1 (en) | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| WO1997026328A1 (en) | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| WO2001044279A2 (en) | 1999-12-17 | 2001-06-21 | Chiron Corporation | Mammalian dishevelled-associated proteins |
| EP1259601A2 (en) | 2000-02-22 | 2002-11-27 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| JP2004503213A (ja) | 2000-03-27 | 2004-02-05 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法 |
| AU2001275246B2 (en) | 2000-06-05 | 2006-06-29 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| US20020048550A1 (en) | 2000-07-20 | 2002-04-25 | Vallera Daniel A. | Radiolabeled immunotoxins |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US20070134261A1 (en) * | 2001-12-03 | 2007-06-14 | Hancock Robert E | Effectors of innate immunity |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| US20040091503A1 (en) * | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| JP4406607B2 (ja) * | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | ペプチド及びこれを含む医薬 |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| NZ539226A (en) | 2002-11-09 | 2008-09-26 | Medigene Ltd | T cell receptor display |
| US20040096982A1 (en) | 2002-11-19 | 2004-05-20 | International Business Machines Corporation | Methods and apparatus for analysis of mass spectra |
| DE602004015064D1 (de) | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US20090233318A1 (en) | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090075304A1 (en) | 2004-05-27 | 2009-03-19 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090304679A1 (en) * | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| PL1760089T3 (pl) | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| US20090117034A1 (en) | 2007-06-15 | 2009-05-07 | Nanhai Chen | Microorganisms for imaging and/or treatment of tumors |
| WO2009026547A1 (en) | 2007-08-22 | 2009-02-26 | Receptor Logi, Ltd. | Methods of assaying vaccine potency |
| PL2201100T3 (pl) | 2007-09-14 | 2016-10-31 | Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu | |
| WO2009108372A2 (en) | 2008-02-27 | 2009-09-03 | Receptor Logic, Inc. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| WO2009151487A1 (en) | 2008-06-13 | 2009-12-17 | Receptor Logic, Inc. | Methods of assaying vaccine potency |
| DE102008049136B4 (de) | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
| DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| WO2010059742A1 (en) * | 2008-11-18 | 2010-05-27 | Collabrx, Inc. | Individualized cancer treatment |
| AU2010319323B2 (en) | 2009-11-14 | 2015-01-15 | Cardiovax, Llc | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| AU2011336997A1 (en) | 2010-11-12 | 2013-05-30 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
| EP2637685A1 (en) | 2010-11-12 | 2013-09-18 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of aneurysms |
| US20130302362A1 (en) * | 2010-11-12 | 2013-11-14 | Cedars-Sinai Medical Center | Immunomodulatory Compositions, Methods and Systems Comprising Immunogenic Fragments of ApoB-100 |
| CA2836299A1 (en) * | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| EP2788012A4 (en) * | 2011-11-11 | 2015-08-05 | Cedars Sinai Medical Center | COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES |
| EP3466439A1 (en) * | 2011-12-09 | 2019-04-10 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| GB201208293D0 (en) | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| GB201209862D0 (en) * | 2012-06-01 | 2012-07-18 | Circassia Ltd | Cladosporium peptides |
| US10682399B2 (en) * | 2012-09-05 | 2020-06-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| GB201301632D0 (en) | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| US9134326B2 (en) * | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| CN103739667B (zh) | 2013-09-24 | 2017-08-25 | 上海宇研生物技术有限公司 | 卵巢癌特异的肿瘤抗原肽及其制备方法 |
| RU2722696C2 (ru) | 2014-03-14 | 2020-06-03 | Иммунокор Лимитед | Библиотеки tcr |
| SG10202102698VA (en) * | 2014-12-23 | 2021-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| US20180179283A1 (en) | 2015-06-08 | 2018-06-28 | Adicet Bio Inc. | T cell receptor like antibodies having fine specificity |
| ES2788188T5 (es) | 2016-04-08 | 2023-10-24 | Adaptimmune Ltd | Receptores de linfocitos T |
| DK3440102T3 (da) | 2016-04-08 | 2024-07-22 | Adaptimmune Ltd | T-cellereceptorer |
| HUE056433T2 (hu) | 2016-04-08 | 2022-02-28 | Adaptimmune Ltd | T-sejt receptorok |
| WO2018022573A1 (en) | 2016-07-27 | 2018-02-01 | Sharp Laboratories Of America, Inc. | Wireless telecommuncations methods and apparatus using system information value tag |
| JP7303750B2 (ja) | 2017-01-24 | 2023-07-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
| US20200325244A1 (en) | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| EP3636761B1 (en) | 2017-06-05 | 2024-07-31 | Mie University | Antigen-binding protein recognizing mage-a4-derived peptide |
| AU2018298422B2 (en) | 2017-07-04 | 2023-04-06 | CureVac SE | Novel nucleic acid molecules |
| JP2021500852A (ja) | 2017-08-18 | 2021-01-14 | グリットストーン オンコロジー インコーポレイテッド | 共有抗原を標的にする抗原結合タンパク質 |
| US12221465B2 (en) | 2017-09-06 | 2025-02-11 | California Institute Of Technology | Signaling and antigen-presenting bifunctional receptors (SABR) |
| CA3086923A1 (en) | 2017-12-28 | 2019-07-04 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared antigens |
| WO2019204683A1 (en) | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| EP3796927A4 (en) | 2018-05-23 | 2022-04-20 | Gritstone bio, Inc. | Shared antigens |
| US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US20200291116A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US20200291127A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
-
2015
- 2015-12-16 SG SG10202102698VA patent/SG10202102698VA/en unknown
- 2015-12-16 HU HUE19170191A patent/HUE055489T2/hu unknown
- 2015-12-16 MA MA49155A patent/MA49155B1/fr unknown
- 2015-12-16 MA MA049156A patent/MA49156A/fr unknown
- 2015-12-16 PT PT158138099T patent/PT3236985T/pt unknown
- 2015-12-16 MD MDE20191122T patent/MD3545965T2/ro not_active IP Right Cessation
- 2015-12-16 ES ES19199101T patent/ES2896919T3/es active Active
- 2015-12-16 HU HUE19199098A patent/HUE057014T2/hu unknown
- 2015-12-16 EP EP24199595.0A patent/EP4461371A3/en active Pending
- 2015-12-16 LT LTEP19199125.6T patent/LT3626731T/lt unknown
- 2015-12-16 MY MYPI2021002573A patent/MY199068A/en unknown
- 2015-12-16 RS RS20211420A patent/RS62575B1/sr unknown
- 2015-12-16 SG SG10202101444UA patent/SG10202101444UA/en unknown
- 2015-12-16 LT LTEP19199101.7T patent/LT3626729T/lt unknown
- 2015-12-16 MD MDE20170224T patent/MD3236985T3/ro not_active IP Right Cessation
- 2015-12-16 PT PT191701911T patent/PT3545965T/pt unknown
- 2015-12-16 MY MYPI2017700826A patent/MY178137A/en unknown
- 2015-12-16 KR KR1020207030041A patent/KR102435015B1/ko active Active
- 2015-12-16 MA MA48487A patent/MA48487B1/fr unknown
- 2015-12-16 DK DK15813809.9T patent/DK3236985T4/da active
- 2015-12-16 PL PL19199125T patent/PL3626731T3/pl unknown
- 2015-12-16 PT PT191991017T patent/PT3626729T/pt unknown
- 2015-12-16 ES ES19199098T patent/ES2900106T3/es active Active
- 2015-12-16 PL PL19170191T patent/PL3545965T3/pl unknown
- 2015-12-16 KR KR1020247006647A patent/KR20240033128A/ko active Pending
- 2015-12-16 MD MDE20200298T patent/MD3626729T2/ro not_active IP Right Cessation
- 2015-12-16 KR KR1020227028464A patent/KR102643923B1/ko active Active
- 2015-12-16 HU HUE19199125A patent/HUE056607T2/hu unknown
- 2015-12-16 HR HRP20211754TT patent/HRP20211754T1/hr unknown
- 2015-12-16 MD MDE20200300T patent/MD3626731T2/ro not_active IP Right Cessation
- 2015-12-16 UA UAA201702214A patent/UA124331C2/uk unknown
- 2015-12-16 ES ES15813809T patent/ES2763911T5/es active Active
- 2015-12-16 PT PT191990985T patent/PT3616706T/pt unknown
- 2015-12-16 CR CR20210289A patent/CR20210289A/es unknown
- 2015-12-16 SI SI201531736T patent/SI3616706T1/sl unknown
- 2015-12-16 PE PE2021000187A patent/PE20211740A1/es unknown
- 2015-12-16 MA MA050819A patent/MA50819A/fr unknown
- 2015-12-16 HR HRP20211327TT patent/HRP20211327T1/hr unknown
- 2015-12-16 LT LTEP19199098.5T patent/LT3616706T/lt unknown
- 2015-12-16 HU HUE19199101A patent/HUE056087T2/hu unknown
- 2015-12-16 MA MA46913A patent/MA46913B1/fr unknown
- 2015-12-16 FI FIEP15813809.9T patent/FI3236985T4/fi active
- 2015-12-16 LT LTEP15813809.9T patent/LT3236985T/lt unknown
- 2015-12-16 MA MA049157A patent/MA49157A/fr unknown
- 2015-12-16 PL PL19199101T patent/PL3626729T3/pl unknown
- 2015-12-16 PT PT191991256T patent/PT3626731T/pt unknown
- 2015-12-16 HR HRP20192212TT patent/HRP20192212T4/hr unknown
- 2015-12-16 KR KR1020207015687A patent/KR102395995B1/ko active Active
- 2015-12-16 ES ES19199125T patent/ES2899425T3/es active Active
- 2015-12-16 HU HUE15813809A patent/HUE046641T2/hu unknown
- 2015-12-16 MD MDE20200241T patent/MD3616706T2/ro not_active IP Right Cessation
- 2015-12-16 ES ES19170191T patent/ES2887107T3/es active Active
- 2015-12-16 HR HRP20211753TT patent/HRP20211753T1/hr unknown
- 2015-12-16 SI SI201531746T patent/SI3626731T1/sl unknown
- 2015-12-16 LT LTEP19170191.1T patent/LT3545965T/lt unknown
- 2015-12-16 HR HRP20211580TT patent/HRP20211580T1/hr unknown
- 2015-12-16 PL PL19199098T patent/PL3616706T3/pl unknown
- 2015-12-21 TW TW109139864A patent/TWI794679B/zh active
- 2015-12-21 TW TW109103806A patent/TWI754892B/zh not_active IP Right Cessation
- 2015-12-21 TW TW112102743A patent/TW202321273A/zh unknown
-
2017
- 2017-03-10 ZA ZA2017/01762A patent/ZA201701762B/en unknown
- 2017-04-19 CO CONC2017/0003772A patent/CO2017003772A2/es unknown
- 2017-06-21 MX MX2020011794A patent/MX2020011794A/es unknown
- 2017-06-21 MX MX2020004757A patent/MX2020004757A/es unknown
- 2017-06-21 MX MX2020005188A patent/MX2020005188A/es unknown
- 2017-06-21 MX MX2020011791A patent/MX2020011791A/es unknown
- 2017-06-21 MX MX2020011787A patent/MX2020011787A/es unknown
- 2017-06-21 MX MX2020011793A patent/MX2020011793A/es unknown
-
2019
- 2019-12-17 CY CY20191101328T patent/CY1122491T1/el unknown
-
2020
- 2020-06-12 JP JP2020102004A patent/JP7109801B2/ja active Active
- 2020-06-12 JP JP2020102005A patent/JP7358299B2/ja active Active
- 2020-06-12 JP JP2020102006A patent/JP2020191866A/ja active Pending
- 2020-06-15 JP JP2020102993A patent/JP7448423B2/ja active Active
- 2020-06-15 JP JP2020102991A patent/JP2020191867A/ja not_active Ceased
- 2020-06-15 JP JP2020102992A patent/JP7346361B2/ja active Active
- 2020-06-19 JP JP2020106475A patent/JP7026411B2/ja not_active Expired - Fee Related
-
2021
- 2021-03-23 IL IL281752A patent/IL281752A/en unknown
- 2021-06-04 CL CL2021001479A patent/CL2021001479A1/es unknown
- 2021-10-01 US US17/492,112 patent/US12076380B2/en active Active
- 2021-10-06 CY CY20211100869T patent/CY1124533T1/el unknown
- 2021-10-15 US US17/502,185 patent/US12121572B2/en active Active
- 2021-10-15 US US17/502,170 patent/US12070491B2/en active Active
- 2021-10-22 US US17/508,295 patent/US20220054613A1/en not_active Abandoned
- 2021-10-22 US US17/508,230 patent/US12097248B2/en active Active
- 2021-11-01 US US17/516,304 patent/US11576956B2/en active Active
- 2021-12-07 CY CY20211101071T patent/CY1124847T1/el unknown
- 2021-12-07 CY CY20211101070T patent/CY1124846T1/el unknown
- 2021-12-15 CY CY20211101104T patent/CY1124813T1/el unknown
-
2022
- 2022-04-25 US US17/728,756 patent/US11559573B2/en active Active
- 2022-06-29 US US17/853,334 patent/US11779638B2/en active Active
- 2022-06-29 US US17/853,344 patent/US11679147B2/en active Active
- 2022-06-29 US US17/852,623 patent/US11672848B2/en active Active
- 2022-11-09 AU AU2022268329A patent/AU2022268329A1/en not_active Abandoned
-
2023
- 2023-05-10 JP JP2023078113A patent/JP2023100927A/ja active Pending
-
2024
- 2024-08-23 US US18/814,073 patent/US20240408166A1/en active Pending
-
2025
- 2025-06-12 JP JP2025098413A patent/JP2025134788A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021101700A5 (enExample) | ||
| JP2020191862A5 (enExample) | ||
| JP2020182458A5 (enExample) | ||
| JP2020198875A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| JP2024041841A5 (enExample) | ||
| JP2019536426A5 (enExample) | ||
| JP2019513005A5 (enExample) | ||
| CA2820617C (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| JP2019515650A5 (enExample) | ||
| HRP20171504T1 (hr) | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom | |
| JP2020516681A5 (enExample) | ||
| JP2020506690A5 (enExample) | ||
| JP2010527919A5 (enExample) | ||
| JP2020517705A (ja) | オリゴマー粒子試薬およびその使用方法 | |
| JP2018529320A5 (enExample) | ||
| JP2013521789A5 (enExample) | ||
| JP2019502360A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2009506762A5 (enExample) | ||
| HRP20160915T1 (hr) | Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga | |
| JP2004525354A (ja) | 抗原特異的ｔ−細胞の機能的精製のための可逆的ｍｈｃ多量体染色法 | |
| JP2020191868A5 (enExample) | ||
| JP2020191873A5 (enExample) | ||
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma |